Mortality and length of hospital stay after bloodstream infections caused by ESBL-producing compared to non-ESBL-producing E. coli

References

• World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report 2021. Geneva. Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Bonten M, Johnson JR, van den Biggelaar AHJ, et al. Epidemiology of Escherichia coli bacteremia: a systematic literature review. Clin Infect Dis. 2021;72(7):1211–1219. doi:10.1093/cid/ciaa210.
   PubMed Web of Science ®Google Scholar
• Laupland KB, Gregson DB, Church DL, et al. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect. 2008;14(11):1041–1047. doi:10.1111/j.1469-0691.2008.02089.x.
   PubMed Web of Science ®Google Scholar
• Vihta K-D, Stoesser N, Llewelyn MJ, et al. Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in oxfordshire, UK, 1998–2016: a study of electronic health records. Lancet Infect Dis. 2018;18(10):1138–1149. doi:10.1016/s1473-3099(18)30353-0.
   PubMed Web of Science ®Google Scholar
• UK Health Security Agency. Quarterly epidemiology commentary: mandatory MRSA, MSSA and gram-negative bacteraemia and C. difficile infection in England (up to October to December 2021). London: UK Health Security Agency; April 2022.
   Google Scholar
• Diekema DJ, Hsueh PR, Mendes RE, et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2019;63(7):e00355-19. doi:10.1128/AAC.00355-19.
   PubMed Web of Science ®Google Scholar
• van der Mee-Marquet NL, Blanc DS, Gbaguidi-Haore H, et al. Marked increase in incidence for bloodstream infections due to Escherichia coli, a side effect of previous antibiotic therapy in the elderly. Front Microbiol. 2015;6:646. doi:10.3389/fmicb.2015.00646.
   PubMed Web of Science ®Google Scholar
• Kontula KSK, Skogberg K, Ollgren J, et al. Population-based study of bloodstream infection incidence and mortality rates, Finland, 2004-2018. Emerg Infect Dis. 2021;27(10):2560–2569. doi:10.3201/eid2710.204826.
   PubMed Web of Science ®Google Scholar
• Gladstone RA, McNally A, Pöntinen AK, et al. Emergence and dissemination of antimicrobial resistance in Escherichia coli causing bloodstream infections in Norway in 2002–17: a nationwide, longitudinal, microbial population genomic study. Lancet Microbe. 2021;2(7):e331–e341. doi:10.1016/s2666-5247(21)00031-8.
   PubMedGoogle Scholar
• Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. doi:10.1016/s0140-6736(21)02724-0.
   PubMed Web of Science ®Google Scholar
• Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant enterobacteriaceae. Clin Microbiol Rev. 2015;28(3):565–591. doi:10.1128/CMR.00116-14.
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60(5):913–920. doi:10.1093/jac/dkm318.
   PubMed Web of Science ®Google Scholar
• Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67(6):1311–1320. doi:10.1093/jac/dks065.
   PubMed Web of Science ®Google Scholar
• MacKinnon MC, Sargeant JM, Pearl DL, et al. Evaluation of the health and healthcare system burden due to antimicrobial-resistant Escherichia coli infections in humans: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020;9(1):200. doi:10.1186/s13756-020-00863-x.
   PubMed Web of Science ®Google Scholar
• Shamsrizi P, Gladstone BP, Carrara E, et al. Variation of effect estimates in the analysis of mortality and length of hospital stay in patients with infections caused by bacteria-producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. BMJ Open. 2020;10(1):e030266. doi:10.1136/bmjopen-2019-030266.
   PubMed Web of Science ®Google Scholar
• Ling W, Furuya-Kanamori L, Ezure Y, et al. Adverse clinical outcomes associated with infections by Enterobacterales producing ESBL (ESBL-E): a systematic review and meta-analysis. JAC Antimicrob Resist. 2021;3(2):dlab068. doi:10.1093/jacamr/dlab068.
   PubMedGoogle Scholar
• Jiang AM, Liu N, Zhao R, et al. Clinical outcomes and prognostic factors in bloodstream infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae among patients with malignancy: a meta-analysis. Ann Clin Microbiol Antimicrob. 2020;19(1):53. doi:10.1186/s12941-020-00395-7.
   PubMed Web of Science ®Google Scholar
• de Lastours V, Laouenan C, Royer G, et al. Mortality in Escherichia coli bloodstream infections: antibiotic resistance still does not make it. J Antimicrob Chemother. 2020;75(8):2334–2343. doi:10.1093/jac/dkaa161.
   PubMed Web of Science ®Google Scholar
• Richelsen R, Smit J, Schonheyder HC, et al. Outcome of community-onset ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and urinary tract infection: a population-based cohort study in Denmark. J Antimicrob Chemother. 2020;75(12):3656–3664. doi:10.1093/jac/dkaa361.
   PubMed Web of Science ®Google Scholar
• Abernethy JK, Johnson AP, Guy R, et al. Thirty day all-cause mortality in patients with Escherichia coli bacteraemia in England. Clin Microbiol Infect. 2015;21(3):251 e1-8–251.e8. doi:10.1016/j.cmi.2015.01.001.
   Web of Science ®Google Scholar
• Liang T, Xu C, Cheng Q, et al. Epidemiology, risk factors, and clinical outcomes of bloodstream infection due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in hematologic malignancy: a retrospective study from Central South China. Microb Drug Resist. 2021;27(6):800–808. doi:10.1089/mdr.2020.0033.
   PubMed Web of Science ®Google Scholar
• NORM/NORM-VET. 2019. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø/Oslo 2020. ISSN:1502-2307 (print)/1890-9965 (electronic). Available from: www.antibiotikaresistens.no.
   Google Scholar
• Giske CG, Sundsfjord AS, Kahlmeter G, et al. Redefining extended-spectrum β-lactamases: balancing science and clinical need. J Antimicrob Chemother. 2009;63(1):1–4. doi:10.1093/jac/dkn444.
   PubMed Web of Science ®Google Scholar
• Thygesen SK, Christiansen CF, Christensen S, et al. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of patients. BMC Med Res Methodol. 2011;11(1):83. doi:10.1186/1471-2288-11-83.
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801–810. doi:10.1001/jama.2016.0287.
   PubMed Web of Science ®Google Scholar
• Friedman ND, Kaye KS, Stout JE, et al. Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137(10):791–797. doi:10.7326/0003-4819-137-10-200211190-00007.
   PubMed Web of Science ®Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0. 2019. Available from: http://www.eucast.org.
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. EUCAST disk diffusion method for antimicrobial susceptibility testing. Manual version 9.0. 2021. Available from: www.eucast.org.
   Google Scholar
• Lin WP, Huang YS, Wang JT, et al. Prevalence of and risk factor for community-onset third-generation cephalosporin-resistant Escherichia coli bacteremia at a medical center in Taiwan. BMC Infect Dis. 2019;19(1):245. doi:10.1186/s12879-019-3880-z.
   PubMedGoogle Scholar
• Xiao T, Wu Z, Shi Q, et al. A retrospective analysis of risk factors and outcomes in patients with extended-spectrum beta-lactamase-producing Escherichia coli bloodstream infections. J Glob Antimicrob Resist. 2019;17:147–156. doi:10.1016/j.jgar.2018.12.014.
   PubMed Web of Science ®Google Scholar
• Jauneikaite E, Honeyford K, Blandy O, et al. Bacterial genotypic and patient risk factors for adverse outcomes in Escherichia coli bloodstream infections: a prospective molecular epidemiological study. J Antimicrob Chemother. 2022;77(6):1753–1761. doi:10.1093/jac/dkac071.
   PubMed Web of Science ®Google Scholar
• Leistner R, Sakellariou C, Gurntke S, et al. Mortality and molecular epidemiology associated with extended-spectrum beta-lactamase production in Escherichia coli from bloodstream infection. Infect Drug Resist. 2014;7:57–62. doi:10.2147/IDR.S56984.
   PubMed Web of Science ®Google Scholar
• Ha YE, Kang CI, Cha MK, et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents. 2013;42(5):403–409. doi:10.1016/j.ijantimicag.2013.07.018.
   PubMed Web of Science ®Google Scholar
• Lefort A, Panhard X, Clermont O, et al. Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia. J Clin Microbiol. 2011;49(3):777–783. doi:10.1128/JCM.01902-10.
   PubMed Web of Science ®Google Scholar
• Sakellariou C, Gurntke S, Steinmetz I, et al. Sepsis caused by extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: comparison of severity of sepsis, delay of anti-infective therapy and ESBL genotype. PLoS One. 2016;11(7):e0158039. doi:10.1371/journal.pone.0158039.
   PubMed Web of Science ®Google Scholar
• Palacios-Baena ZR, Gutierrez-Gutierrez B, De Cueto M, et al. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-beta-lactamase-producing enterobacteriaceae. J Antimicrob Chemother. 2017;72(3):906–913. doi:10.1093/jac/dkw513.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Antimicrobial resistance: global report on surveillance. 2014. France. Available from: https://www.who.int/publications/i/item/9789241564748.
   Google Scholar
• Rhee C, Jones TM, Hamad Y, et al. Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals. JAMA Netw Open. 2019;2(2):e187571. doi:10.1001/jamanetworkopen.2018.7571.
   PubMed Web of Science ®Google Scholar
• Tocut M, Zohar I, Schwartz O, et al. Short- and long-term mortality in patients with urosepsis caused by Escherichia coli susceptible and resistant to 3rd generation cephalosporins. BMC Infect Dis. 2022;22(1):571. doi:10.1186/s12879-022-07538-5.
   PubMed Web of Science ®Google Scholar
• Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, et al. Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance. Clin Infect Dis. 2020;70(6):1068–1074. doi:10.1093/cid/ciz319.
   PubMed Web of Science ®Google Scholar
• Joo EJ, Park DA, Lee NR, et al. Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-beta-lactamase producing Escherichia coli and klebisella pneumoniae definitively treated with carbapenems. Eur J Clin Microbiol Infect Dis. 2017;36(11):2093–2100. doi:10.1007/s10096-017-3031-7.
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Cataldo MA, Mutters NT, et al. Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum beta-lactamase-producing enterobacteriaceae infections. Int J Antimicrob Agents. 2019;54(1):49–54. doi:10.1016/j.ijantimicag.2019.04.007.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Zhao Q, Fahrbach K, et al. A systematic review of the association between delayed appropriate therapy and mortality among patients hospitalized with infections due to Klebsiella pneumoniae or Escherichia coli: how long is too long? BMC Infect Dis. 2018;18(1):625. doi:10.1186/s12879-018-3524-8.
   PubMedGoogle Scholar
• Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181–1247. doi:10.1007/s00134-021-06506-y.
   PubMed Web of Science ®Google Scholar
• Naylor NR, Pouwels KB, Hope R, et al. The health and cost burden of antibiotic resistant and susceptible Escherichia coli bacteraemia in the english hospital setting: a national retrospective cohort study. PLoS One. 2019;14(9):e0221944. doi:10.1371/journal.pone.0221944.
   PubMed Web of Science ®Google Scholar
• Richelsen R, Smit J, Laxsen Anru P, et al. Risk factors of community-onset extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae bacteraemia: an 11-year population-based case-control-control study in Denmark. Clin Microbiol Infect. 2021;27(6):871–877. doi:10.1016/j.cmi.2020.08.004.
   PubMed Web of Science ®Google Scholar
• Biehl LM, Schmidt-Hieber M, Liss B, et al. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients – review of the literature from a clinical perspective. Crit Rev Microbiol. 2016;42(1):1–16. doi:10.3109/1040841X.2013.875515.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Picon E, Gijon P, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010;50(1):40–48. doi:10.1086/649537.
   PubMed Web of Science ®Google Scholar
• Isendahl J, Giske CG, Hammar U, et al. Temporal dynamics and risk factors for bloodstream infection with extended-spectrum beta-lactamase-producing bacteria in previously-colonized individuals: national population-based cohort study. Clin Infect Dis. 2019;68(4):641–649. doi:10.1093/cid/ciy539.
   PubMed Web of Science ®Google Scholar
• Akerlund A, Jonasson E, Matuschek E, et al. EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 european laboratories. J Antimicrob Chemother. 2020;75(11):3230–3238. doi:10.1093/jac/dkaa333.
   PubMed Web of Science ®Google Scholar
• Rello J, van Engelen TSR, Alp E, et al. Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. 2018;24(12):1264–1272. doi:10.1016/j.cmi.2018.03.011.
   PubMed Web of Science ®Google Scholar